Market Cap 186.57M
Revenue (ttm) 53.40M
Net Income (ttm) 2.93M
EPS (ttm) N/A
PE Ratio 33.71
Forward PE 18.15
Profit Margin 5.49%
Debt to Equity Ratio 0.00
Volume 1,164,900
Avg Vol 645,890
Day's Range N/A - N/A
Shares Out 79.73M
Stochastic %K 86%
Beta -0.13
Analysts Strong Sell
Price Target $14.00

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 696 9345
Address:
2 University Plaza, Suite 100, Hackensack, United States
pmcd777
pmcd777 Oct. 5 at 1:04 AM
$PLX Elfabrio was on PRAC agenda for meeting that was just held
1 · Reply
PRX102
PRX102 Oct. 4 at 4:16 PM
$PLX Wensite redesign … saying we”re available without exactly saying “we’re available” ( for BO)?🤔
1 · Reply
pmcd777
pmcd777 Oct. 4 at 1:37 PM
$PLX the EMA Management Board met yesterday. https://www.ema.europa.eu/en/news/improving-efficiency-approval-process-new-medicines-eu
2 · Reply
gian_
gian_ Oct. 4 at 12:54 PM
$PLX Part 2) This is a preview of why this drug could be worth billions of dollars. The main findings were that, first, pre-existing ADAs against agalsidase alfa and beta showed significantly lower affinity for pegunigalsidase alfa; second, the lower affinity also resulted in reduced inhibitory capacity (30%) of the pre-existing ADAs against pegunigalsidase alfa and less impact on cellular uptake of pre-existing ADAs against pegunigalsidase. In summary, the study demonstrates lower affinity and enzyme inhibition (including cellular activity and uptake) of pre-existing ADAs against pegunigalsidase alfa, resulting in decreased ADA-mediated enzyme inhibition and reduced ADA interference.
0 · Reply
gian_
gian_ Oct. 4 at 12:53 PM
$PLX Part 1) I have an early appointment tomorrow morning for an immunological procedure, but first I need to introduce two important concepts that need to be understood: 1) Affinity of antibodies (ADA) for the enzyme High affinity = the antibody "sticks" very strongly to the enzyme (like a powerful magnet). Low affinity = the antibody binds only weakly and detaches more easily. In studies, ADA formed against agalsidase alpha/beta bind much less well to pegunigalsidase alpha (Elfabrio), meaning the drug is able to partially "escape" the action of the antibodies. 2. Inhibitory capacity ADA not only bind, but can block the enzyme's activity: They prevent the enzyme from "cutting" and degrading Gb3, and can also hinder the enzyme's entry into cells (cellular uptake).
0 · Reply
PLX_BULLS
PLX_BULLS Oct. 3 at 11:46 PM
$PLX This is going to help our tute average big time! BMI inclusion is going to add a few million shares worth of purchases. The Russell 2-3k brought 7-8m worth of share purchases!
1 · Reply
pmcd777
pmcd777 Oct. 3 at 11:31 PM
$PLX research article on elelyso published today https://www.mdpi.com/2077-0383/14/19/7015
1 · Reply
flyinghollaender
flyinghollaender Oct. 3 at 11:28 PM
$PLX we‘ll know more next week
2 · Reply
PLX_BULLS
PLX_BULLS Oct. 3 at 11:16 PM
$PLX I see a spike to 7$ if we get positive EMA decision and milestone. Warrants, Debt, and Notes are gone and freebies handed out, eg. little resistance. Larger tute presence and more adding everyday. Earnings will be really good too!
1 · Reply
Social_Idiot
Social_Idiot Oct. 3 at 9:58 PM
$PLX what is sbu.me? https://protalix.sbu.me/home Not joking this time.
4 · Reply
Latest News on PLX
Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 11, 2025, 10:55 AM EDT - 23 days ago

Protalix BioTherapeutics to Present at Investor Summit Virtual


Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 23, 2024, 6:50 AM EST - 10 months ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders


Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Dec 26, 2023, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders


pmcd777
pmcd777 Oct. 5 at 1:04 AM
$PLX Elfabrio was on PRAC agenda for meeting that was just held
1 · Reply
PRX102
PRX102 Oct. 4 at 4:16 PM
$PLX Wensite redesign … saying we”re available without exactly saying “we’re available” ( for BO)?🤔
1 · Reply
pmcd777
pmcd777 Oct. 4 at 1:37 PM
$PLX the EMA Management Board met yesterday. https://www.ema.europa.eu/en/news/improving-efficiency-approval-process-new-medicines-eu
2 · Reply
gian_
gian_ Oct. 4 at 12:54 PM
$PLX Part 2) This is a preview of why this drug could be worth billions of dollars. The main findings were that, first, pre-existing ADAs against agalsidase alfa and beta showed significantly lower affinity for pegunigalsidase alfa; second, the lower affinity also resulted in reduced inhibitory capacity (30%) of the pre-existing ADAs against pegunigalsidase alfa and less impact on cellular uptake of pre-existing ADAs against pegunigalsidase. In summary, the study demonstrates lower affinity and enzyme inhibition (including cellular activity and uptake) of pre-existing ADAs against pegunigalsidase alfa, resulting in decreased ADA-mediated enzyme inhibition and reduced ADA interference.
0 · Reply
gian_
gian_ Oct. 4 at 12:53 PM
$PLX Part 1) I have an early appointment tomorrow morning for an immunological procedure, but first I need to introduce two important concepts that need to be understood: 1) Affinity of antibodies (ADA) for the enzyme High affinity = the antibody "sticks" very strongly to the enzyme (like a powerful magnet). Low affinity = the antibody binds only weakly and detaches more easily. In studies, ADA formed against agalsidase alpha/beta bind much less well to pegunigalsidase alpha (Elfabrio), meaning the drug is able to partially "escape" the action of the antibodies. 2. Inhibitory capacity ADA not only bind, but can block the enzyme's activity: They prevent the enzyme from "cutting" and degrading Gb3, and can also hinder the enzyme's entry into cells (cellular uptake).
0 · Reply
PLX_BULLS
PLX_BULLS Oct. 3 at 11:46 PM
$PLX This is going to help our tute average big time! BMI inclusion is going to add a few million shares worth of purchases. The Russell 2-3k brought 7-8m worth of share purchases!
1 · Reply
pmcd777
pmcd777 Oct. 3 at 11:31 PM
$PLX research article on elelyso published today https://www.mdpi.com/2077-0383/14/19/7015
1 · Reply
flyinghollaender
flyinghollaender Oct. 3 at 11:28 PM
$PLX we‘ll know more next week
2 · Reply
PLX_BULLS
PLX_BULLS Oct. 3 at 11:16 PM
$PLX I see a spike to 7$ if we get positive EMA decision and milestone. Warrants, Debt, and Notes are gone and freebies handed out, eg. little resistance. Larger tute presence and more adding everyday. Earnings will be really good too!
1 · Reply
Social_Idiot
Social_Idiot Oct. 3 at 9:58 PM
$PLX what is sbu.me? https://protalix.sbu.me/home Not joking this time.
4 · Reply
Wealthy500
Wealthy500 Oct. 3 at 9:58 PM
$PLX good question. Maybe 8 - 14$ ...not sure.
2 · Reply
jeremy0916
jeremy0916 Oct. 3 at 9:21 PM
$PLX 2 weeks away from chmp decision 🔥.
0 · Reply
Social_Idiot
Social_Idiot Oct. 3 at 8:54 PM
$PLX OMG! Checkout https://chiesi.protalix.com
1 · Reply
Thinkapp
Thinkapp Oct. 3 at 8:43 PM
$PLX dror, could you fix your website or just let us know you are taking down the site.
0 · Reply
PLX_BULLS
PLX_BULLS Oct. 3 at 8:01 PM
$PLX We’re looking good longs!!!
0 · Reply
PLX_BULLS
PLX_BULLS Oct. 3 at 7:01 PM
$PLX be nice to see it run up to 2.45 or so for the close. Shorts should cover!
1 · Reply
crackpot
crackpot Oct. 3 at 5:53 PM
$PLX flipped for 3 cents……JK. in this for retirement funds for grandkids
0 · Reply
Artfldgr
Artfldgr Oct. 3 at 4:52 PM
1 · Reply
Artfldgr
Artfldgr Oct. 3 at 4:51 PM
$PLX a shitload of 4s came out AI quick summary insiders are being incentivized to stay and benefit from appreciation. It’s not a surprise raise or ATM usage. If anything, it reduces the odds of dilution in the very near term because the board just gave everyone cheap stock; they don’t want to crater it right away. Not dilution: these are compensation grants from the existing equity incentive pool, not new financings. Alignment: insiders only benefit if PLX trades above $1.64 in the long run, which is already the case at today’s ~$2.30–$2.50. Signal: blanket option grants across management + directors can mean the board is locking in retention right before a potential inflection (milestones, partnerships, or M&A). It’s common to issue options when they think the stock is undervalued and events are ahead. Optics: sometimes traders worry this means “they’ll sell later,” but the strike price + 12-quarter vesting means these are sticky. They don’t turn into free tradable shares overnight.
0 · Reply
CliffordCapital
CliffordCapital Oct. 3 at 4:45 PM
$PLX facing serious resistance around the 2.60$ area. I am sorry but this can‘t go on forever unfortunately. We‘ll likely see a major pullback soon! Hoping for a week or two of consolidation before we test the 3$ area. I pray that we gonna see 5$ with good ER’s and positive opinion…There are company’s out there like (PRME) trading at billion $ valuations with zero products on the market… we should easily be worth 500M right now.
1 · Reply
GMH21
GMH21 Oct. 3 at 4:23 PM
$PLX This seems to me to be positioning in preparation for the monthly dosing decision. CHMP agenda should be released mid next week. Run-up may be at risk of not being on agenda as well as decision itself. Positive opinion and the run should continue.
1 · Reply
Thinkapp
Thinkapp Oct. 3 at 4:17 PM
$PLX please give us a HALT and release us from waiting
1 · Reply